LAMH Group

LAMH is a cancer early detection and diagnostic company focused on AI-driven, blood-based screening tests, with operations in China and the United States. The company commercializes liver cancer screening products including Ganbeikang in China and HelioLiver in the U.S., and it reports having the first NMPA-approved liver cancer early screening registration certificate globally. Its technology stack centers on cfDNA methylation analysis, multi-omics biomarker integration, and proprietary bioinformatics methods such as CHALM and MESA. LAMH also operates testing laboratories and GMP manufacturing infrastructure, positioning it as an integrated early cancer screening company spanning R&D, regulatory approval, manufacturing, and commercialization. Beyond liver cancer, the company describes programs in colorectal, lung, breast, and pan-cancer early detection.